Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A stabilized oral formulation of the BPC-157 pentadecapeptide sequence designed for gastrointestinal applications. Unlike standard BPC-157 which is typically injected, this formulation uses stabilization techniques to survive gastric acid degradation. Primarily studied for gut healing, ulcer protection, and inflammatory bowel conditions.
The oral formulation of BPC-157, distinct from the injectable form in its bioavailability profile and primary applications. While injectable BPC-157 is used for systemic and musculoskeletal healing, oral BPC-157 is particularly relevant for gastrointestinal conditions where direct gut exposure may be more important than systemic absorption.
Same core mechanism as BPC-157 — upregulates growth factor expression (VEGF, EGF), promotes angiogenesis, and modulates the nitric oxide system. The oral formulation targets the GI tract directly, providing local healing effects on the gastric and intestinal mucosa before systemic absorption.
Same mechanism as injectable BPC-157 — promotes angiogenesis, upregulates growth factors, and modulates nitric oxide synthesis. In oral form, the peptide is exposed directly to the GI tract mucosa before any systemic absorption, potentially making it more effective for gut-specific conditions.
- Gut healing and repair
- Gastric ulcer protection
- Inflammatory bowel support
- Leaky gut syndrome (investigational)
- NSAID-induced GI damage protection
- Inflammatory bowel disease (IBD)
- Leaky gut and intestinal permeability
- NSAID-induced gastric damage
- Gut healing and GI protection
- Esophageal and stomach ulcers
- Limited human clinical data
- GI discomfort possible
- Uncertain bioavailability compared to injectable
- Quality varies significantly between suppliers
- Not FDA-approved for any indication
- Lower and more variable systemic bioavailability than injectable
- Limited human clinical data for oral form specifically
- Quality of oral preparations varies significantly
- Long-term safety unknown
Shares regulatory status with BPC-157. Removed from Category 2 on April 22, 2026. Awaiting PCAC review at the July 23, 2026 meeting. The oral formulation is not separately categorized by the FDA — it falls under the same BPC-157 regulatory umbrella.
PCAC: 2026-07-23
Shares the same regulatory status as injectable BPC-157 — removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026. The oral form is particularly relevant for the FDA's listed indication of ulcerative colitis. Compounding not yet authorized.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.